Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-04
2006-04-04
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000, C514S227800, C514S235800, C514S252180, C514S318000, C514S341000, C514S343000, C514S353000, C540S575000, C540S597000, C544S060000, C544S131000, C544S360000, C546S194000, C546S272700, C546S276400, C546S306000
Reexamination Certificate
active
07022695
ABSTRACT:
Thioether-substituted benzamide compounds having the formula:are provided that exhibit exceptionally strong inhibition of Factor Xa in combination with weak hERG binding.
REFERENCES:
patent: 4588587 (1986-05-01), Gasic
patent: 6376515 (2002-04-01), Zhu et al.
patent: 6835739 (2004-12-01), Zhu et al.
patent: 2003/0069250 (2003-04-01), Zhu et al.
patent: 2004/0077690 (2004-04-01), Zhu et al.
patent: 0 798 295 (1997-10-01), None
patent: 94/13693 (1994-06-01), None
patent: 97/21437 (1997-06-01), None
patent: 98/28269 (1998-07-01), None
patent: 99/10316 (1999-04-01), None
Turpie, Am. J. Health Syst. Pharm., 60(22 Suppl. 7), S20-4, Nov. 15, 2003.
Gresele et al., Trends in Pharmacological Sciences, 23(1), 25-32, Jan. 2002.
Tan et al., Expert Opin. Investig. Drugs, 12(5), 799-804, 2003.
Berge, S.M. et al., “Pharmaceutical Salts” J. Pharmac. Sci. 66:1-19 (1977).
Cheng, Y. et al., “Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction” Biochem. Pharmacol. 22(23):3099-108 (1973).
Claeson, G., “Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system” Blood Coag. Fibrinol. 5:411-436 (1994).
Elodi et al., “Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation” Thromb. Res. 15:617-629 (1979).
Finlayson,K. et al., “[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen” European J. Pharmacol. 430:147 (2001).
Hautmann, J. et al., “Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors” Thromb. Haemost. 63:220-223 (1990).
Haverkamp, W. et al., “The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology” Cardiovasc. Res. 47:219-33 (2000).
Hitomi, Y. et al., “Inhibitory effect of new syntheic protease inhibitor (FUT-175) on the coagulation system” Haemostasis 15:164-168 (1985).
Kam, C. et al., “Mechanism based isocoumarin inhibitors for trypsin and blood coagulation serine proteases: New anticoagulants” Biochemistry 27:2547-2557 (1988).
Kuzmic, P. et al., “High-throughput screening of enzyme inhibitors: Automatic determination of tightbinding inhibition constants” ANal. Biochem. 281:62-67 (2000).
Netzer, R. et al., “Screening lead compounds for QT interval prolongation” Drug Discovery Today 6:78-84 (2001).
Nutt, E. et al., “The amino acid sequence of antistasin, a potent inhibitor of factor Xa reveals a repeated internal structure” J. Biol. Chem. 263:10162-10167 (1988).
Pearlstein, R. et al., “Characterization of HERG potassium channel inhibition using CoMSIA 3D QSAR and homology modeling approaches” Bioorg. Med. Chem. Lett. 13:1829-35 (2003).
Redfern, W. et al., “Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development” Cardiovasc. Res. 58:32-45 (2003).
Sturzebecher, J. et al., “Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency” Thromb. Res. 54:245-252 (1989).
Tidewell, R. et al., “Strategies for anticoagulation with synthetic protease inhibitors. Xa versus thrombin inhibitors” Thromb. Res. 19:339-349 (1980).
Turner, A. et al., “p-Amidino esters as irreversible inhibitors of factor IXa and Xa and thrombin” Biochemistry 25:4929-4935 (1986).
Waxman, L. et al., “Tick anitcoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa” Science 248:593-596 (1990).
Zhou, Z et al., “Properties of HERG stably expressed in HEK293 cells studied at physiological tempurature” Biophys. J. 74:230-241 (1998).
Goldman Erick A.
Huang Wenrong
Zhang Penglie
Zhu Bing-Yan
Millennium Pharmaceuticals Inc.
Powers Fiona T.
Townsend and Townsend / and Crew LLP
LandOfFree
Thioether-substituted benzamides as inhibitors of Factor Xa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thioether-substituted benzamides as inhibitors of Factor Xa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thioether-substituted benzamides as inhibitors of Factor Xa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3603838